Cell Therapeutics suspends Xyotax enrollment

CTIC suspended enrollment in the Phase III PIONEER trial of Xyotax paclitaxel poliglumex to look at differences in early cycle deaths observed

Read the full 224 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE